Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues

Executive Summary

Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.

You may also be interested in...

EMA Restricts Sanofi's Lemtrada Use, Initiates Risk-Benefit Review

Labeling changes for the multiple sclerosis drug being mandated by European regulators were made to the US label in January.

Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator

The Phase IIb-ready, glutamate-modulating candidate shelved by Pfizer after a portfolio review will help Biogen offset the risk posed by its Phase III Alzheimer's candidate aducanumab.

EMA Calls For Zinbryta's ‘Immediate’ Suspension After More Reports of Brain Disorders

Biogen/AbbVie’s Zinbryta is already being withdrawn worldwide, but EMA now wants the MS drug recalled after mounting reports of serious brain disorders.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts